Cargando…

A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

OBJECTIVES: Using the case study of patisiran and inotersen, we conducted a narrative comparative analysis of the health technology assessment (HTA) agency appraisals of these two first-in-class transthyretin gene silencers, which represent exceptional advances in the treatment of hereditary transth...

Descripción completa

Detalles Bibliográficos
Autor principal:	Iannazzo, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AboutScience 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616187/ https://www.ncbi.nlm.nih.gov/pubmed/36627862 http://dx.doi.org/10.33393/grhta.2021.2193

Ejemplares similares

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
por: Mathew, Veena, et al.
Publicado: (2019)

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019)

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)

Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran
por: Rizk, Malak, et al.
Publicado: (2017)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
por: Gales, Luís
Publicado: (2019)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020)

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
por: Yu, Rosie Z., et al.
Publicado: (2020)

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
por: Suzuki, Yuta, et al.
Publicado: (2021)

Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation
por: Bulinski, Catherine, et al.
Publicado: (2022)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment
por: Severi, Daniele, et al.
Publicado: (2022)

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
por: Suhr, Ole B, et al.
Publicado: (2015)

Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
por: Brannagan, Thomas H., et al.
Publicado: (2022)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2019)

Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2020)

Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR
por: Yarlas, Aaron, et al.
Publicado: (2021)

Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)
por: Adams, David, et al.
Publicado: (2015)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2017)

Vial Sharing of High-Cost Drugs to Decrease Leftovers and Costs: A Retrospective Observational Study on Patisiran Administration in Bologna, Italy
por: Cozzio, Margherita, et al.
Publicado: (2023)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

Methods of international health technology assessment agencies for economic evaluations- a comparative analysis
por: Mathes, Tim, et al.
Publicado: (2013)

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
por: Brannagan, T. H., et al.
Publicado: (2020)

International practices in health technology assessment and public financing of digital health technologies: recommendations for Hungary
por: Mezei, Fruzsina, et al.
Publicado: (2023)

Simultaneous silencing of two different Arabidopsis genes with a novel virus-induced gene silencing vector
por: Wu, Kunxin, et al.
Publicado: (2021)

Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?
por: Nielsen, Troels T., et al.
Publicado: (2013)

Generation of a new transgenic mouse model for assessment of tau gene silencing therapies
por: Fromholt, Susan, et al.
Publicado: (2016)

Novel Targeted Therapy for Neuroblastoma: Silencing the MXD3 Gene Using siRNA
por: Duong, Connie, et al.
Publicado: (2017)

Gene silencing by RNA interference : technology and application /
Publicado: (2005)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eldf9ihqe0a8v9qdlqqksnqte9